Price
$12.11
Decreased by -1.38%
Dollar volume (20D)
5.60 M
ADR%
5.30
Earnings report date
Nov 5, 2024
Shares float
43.76 M
Shares short
7.16 M [16.37%]
Shares outstanding
68.32 M
Market cap
838.99 M
Beta
1.21
Price/earnings
N/A
20D range
9.94 12.64
50D range
9.84 12.86
200D range
4.92 12.86

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.

The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.

Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.

The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells.

Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Aug 8, 24 -0.78
Decreased by -4.00%
-0.85
Increased by +8.24%
May 16, 24 -0.82
Decreased by -10.81%
-0.79
Decreased by -3.80%
Feb 8, 24 -0.77
Decreased by -11.59%
-0.93
Increased by +17.20%
Nov 7, 23 -0.90
Decreased by -13.92%
-0.86
Decreased by -4.65%
Aug 3, 23 -0.75
Increased by +3.85%
-0.84
Increased by +10.71%
May 18, 23 -0.74
Decreased by -23.33%
-0.67
Decreased by -10.45%
Feb 9, 23 -0.69
Decreased by -21.05%
-0.75
Increased by +8.00%
Nov 3, 22 -0.79
Decreased by -41.07%
-0.78
Decreased by -1.28%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 24 0.00
Decreased by N/A%
-53.77 M
Decreased by -8.51%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 4.04 M
Increased by +N/A%
-55.08 M
Decreased by -11.85%
Decreased by -1.36 K%
Decreased by N/A%
Dec 31, 23 0.00
Decreased by N/A%
-51.12 M
Decreased by -28.80%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-60.04 M
Decreased by -39.31%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-49.55 M
Decreased by -17.28%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-49.24 M
Decreased by -55.35%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-39.69 M
Decreased by -33.75%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-43.10 M
Decreased by -46.83%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY